As of my last update in October 2023, DDO-02267, identified by its CAS number 2919768-58-2, is a chemical compound that has garnered interest in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as its molecular structure, physical properties, and biological activity may not be widely documented in public databases, compounds like DDO-02267 are typically evaluated for their solubility, stability, and reactivity. They may also undergo extensive testing for efficacy and safety in biological systems. The compound's design likely targets specific biological pathways or receptors, making it a candidate for further research in drug development. For precise information regarding its characteristics, including detailed chemical properties, synthesis methods, and biological effects, consulting specialized scientific literature or databases would be necessary. Always ensure to refer to the latest research for the most accurate and comprehensive data on such compounds.

DDO-02267

2919768-58-2: As of my last update in October 2023, DDO-02267, identified by its CAS number 2919768-58-2, is a chemical compound that has garnered interest in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as its molecular structure, physical properties, and biological activity may not be widely documented in public databases, compounds like DDO-02267 are typically evaluated for their solubility, stability, and reactivity. They may also undergo extensive testing for efficacy and safety in biological systems. The compound's design likely targets specific biological pathways or receptors, making it a candidate for further research in drug development. For precise information regarding its characteristics, including detailed chemical properties, synthesis methods, and biological effects, consulting specialized scientific literature or databases would be necessary. Always ensure to refer to the latest research for the most accurate and comprehensive data on such compounds.

<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>

CAS 2919768-58-2

DDO-02267

DDO-02267

Ref: TM-T204967